High-dose tamoxifen in breast cancer bone metastasis

Journal of B.U.ON.

Volumn 18, Issue 2, 2013, Pages 532-534

  Stathopoulos, George P ^a   Trafalis, D ^a  

^a Errikos Dunant Hospital   (Greece)

Author keywords

Bone metastasis high dose tamoxifen; Breast cancer

Indexed keywords

PAMIDRONIC ACID; TAMOXIFEN; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; LOW DRUG DOSE; OSTEOLYSIS; QUALITY OF LIFE;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84879589962     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Couldwell WT, Hinton DR, Surnock AA et al. Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin Cancer Res 1996; 2: 619-621.
2. Couldwell WT, Weiss MH, DeGiorgio CM et al. Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery 1993; 32: 485-489.
3. Pierce KH Chow, Bee-Choo Tai, Chee-Kiat Tan et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: multicenter randomized controlled trial. Hepatology 2002; 36: 1221-1226.
4. Bergan RC, Reed E, Myers CE et al. A phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. Clin Cancer Res 1999; 5: 2366-2373. (Pubitemid 29437315)
5. Berman E, McBride M, Lin S, Menedez-Botet C, Tong W. Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia. Leukemia 1995; 9:1631-1637.
6. Trump DL, Smith DC, Ellis PG et al. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst 1992; 84: 1811-1816.
7. Watkins SM. The value of high dose tamoxifen in postmenopausal breast cancer patients progressing on standard doses: a pilot study. BJC 1988; 57:320-321. (Pubitemid 18096347)
8. Gershanovich M, Hayes DF, Ellmen J, Vuorinen J. High-dose toremifene vs tamoxifen in postmenopausal advanced breast cancer. Oncology (Williston Park) 1997; 11(5 Suppl 4):29-36. (Pubitemid 27262887)
9. Love RR, Cameron L, Connell BL. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 1991; 151: 1842-1847.
10. Dewar JA, Horobin JM, Preece PE et al. Long term effects of tamoxifen on blood lipid values in breast cancer. BMJ 1992; 305: 225-226.
11. Love RR, Mazess RB, Barden HS et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326: 852-856.
12. Powles TJ, Hickish T, Kanis JA et al. Effect of tamoxifen on bone mineral density by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996; 14: 78-84. (Pubitemid 26022463)
13. Jordan VC, Phelps E, Lindgren JU. Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 1987; 10: 31-35. (Pubitemid 18038542)
14. Turner RT, Wakley GK, Hannon KS, Bell NH. Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone-deficient rats. Endocrinology 1988; 122: 1146-1150. (Pubitemid 18082080)
15. Wakely GK, Baum BL, Hannon KS, Turner RT. The effects of tamoxifen on osteopenia induced by sciatic neurotomy in the rat: a histomorphometric study. Calcif Tissue Int 1988; 43: 383-388. (Pubitemid 19006487)
16. Steward PJ, Stern PH. Effects of the antiestrogens tamoxifen and clomiphene on bone resorption in vitro. Endocrinology 1986; 118: 125-131. (Pubitemid 16186423)
17. Riggs BL, Melton LJ, III. Involutional osteoporosis. N Engl J Med 1986; 314: 1676-1686. (Pubitemid 16097845)
18. Love RR, Mazess RB, Tormey DC, Barden HS, Newcomb PA, Jordan VC. Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast Cancer Res Treat 1988; 12: 297-302.
19. Fentiman IS, Caleffi M, Rodin A, Murby B, Fogelman I. Bone mineral content of women receiving tamoxifen for mastalgia. Br J Cancer 1989; 12: 297-302.
20. Fornander T, Rutqvist LE, Sjöberg HE, Blomqvist L, Mattsson A, Glas U. Long-term adjuvant tamoxifen in early breast cancer: effect on bone mineral density in postmenopausal women. J Clin Oncol 1990; 8: 1019-1024. (Pubitemid 20200189)